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The formulation of pharmaceutical policy is a critical component of healthcare planning, made more important
given that medicines are the ubiquitous technology in the diagnosis, treatment and prevention of disease and
constitute a significant proportion of health care expenditure. Pharmacists need to inform policy development that
will, in its implementation, offer opportunity to deliver greater rationality, safety, effectiveness and economy to the
medicines use process and where patients experience enhanced health outcomes.
This is the second of two articles directed to this specific issue focusing on how policy and strategic change can be
affected. This is discussed from three overlapping perspectives – from the point of view of skills, that is, the skills or
tactics needed to be employed to effect change; secondly, from a structural standpoint in terms of what positional
arrangements exist that could be positively exploited; and thirdly, the subject, particularly its relevance to the
contemporary situation. These approaches are then exemplified through a worked example on medication safety
and its application in practice.
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InfluencingBackground
Part 1 of this two part series commentary set out a num-
ber of practice challenges around pharmacy and medi-
cines management, their implications for policy and the
need for a balanced approach. It highlighted some key
learning points in respect of formulating and implement-
ing national medicines policies and cited a range of au-
thoritative evidence sources to inform the development of
pharmaceutical practice and medicines management pol-
icies. Emphasis was placed on the critical importance of
the pharmaceutical profession to engage with national
policy makers allied to the strategic planning for health
care, as well as a commitment to measuring outcomes of
pharmaceutical initiatives or interventions.
The conference report on the Asia Pacific Conference
on National Medicines Policies made the following ob-
servation that sets a challenging context for influential
engagement.Correspondence: norman.morrow@rpharms.com
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unless otherwise stated.‘In a number of countries, the early gains in national
medicines policy implementation have been lost due to a
lack of ongoing political commitment and loss of policy
champions. Governments need to recognise the import-
ance of a strong legislative framework and a commitment
to enforcing the law. Existing systems need to be strength-
ened and financial resources mobilised to address regional
problems in providing access to medicines of appropriate
quality, safety and efficacy. National medicines policies
and activities to support them need to be presented as a
compelling business case for governments to support and
resource’ [1].
Engagement is, however, often easier said than done,
especially if there has not been any history of involvement
or where pharmaceutical considerations have been mar-
ginalised or even where pharmaceutical advice has been
sourced from non-pharmacists. The question then be-
comes, ‘How is involvement and influence to be effected?’
Further, given success in initiating new actions, assessing
processes and measuring outcomes will be crucial to fu-
ture planning and potential new resource commitment.is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the complexities and cost of evaluation.
Main text
One way of addressing the engagement issue is to think
of it from three overlapping perspectives (Figure 1) – from
the point of view of skills, that is, the skills or tactics
needed to be employed to effect change - the behavioural
component; secondly, from a structural standpoint in
terms of what positional arrangements exist that could be
positively exploited - the environmental or organisational
component; and thirdly, the subject, particularly its rele-
vance to the contemporary situation - the content or the-
matic component.
Influencing and persuading skills
This is probably best thought of in terms of influencing
and persuading skills at the inter-professional interface,
embracing, for example, health and social care profes-
sionals, policy makers and financial advisors. Health care
systems have changed and are changing from those of
exclusive professional domains to those where teamwork,
multidisciplinary collaboration and integrated working
offer greater benefit [2].
Such changes, however, create new demands and chal-
lenges for health professionals, not only in negotiating
one’s own needs, roles and responsibilities but in under-
standing those of others and mindful of the interests of
patients and the need to provide for their optimal care
[3,4]. Being able to influence others and persuade them
to a particular point of view or course of action will be
critical to effective inter-professional communication, as
it will to meaningful engagement in designing and deliv-
ering health care. The tactics used in influencing andSubjectStructures
Skills
Figure 1 Influencing perspectives.persuading others can be summarised under the following
nine categories [5]. In effect, they show how their applica-
tion can offer a better chance of success but also how and
why failure may have been experienced in the past.Power
Power may be expressed in six different ways. Expert
power derives from being recognised as an expert in a
particular field or possessing in-depth knowledge such
that the credibility of expressed views is highly influen-
tial. Referent power can be used to associate ourselves,
our views or practices, with those of other leading indi-
viduals and therefore give more credibility to our pos-
ition, or elicit in others the desire to be similarly aligned.
Legitimate power is a function of a hierarchical position,
as distinct from the person and could, for example, reflect
an employer-employee relationship. Being able to reward
others if they comply with a request is an example of re-
ward power, whereas coercive power stems from being able
to enforce one’s will under threat of sanctions. Finally, in-
formation power is based on the content of the message
such that a pharmacist publishing a safety notice following
a number of adverse events is likely to influence subse-
quent practice.Threat/Fear
This tactic employs the use of fear arousing messages
and the threat of adverse outcomes in order to gain com-
pliance to a particular course of action. Such an approach
is widely used in public health campaigns to warn against
the dangers of, for example, smoking, sunburn, malaria or
tuberculosis and designed to elicit protective behaviour.
The evidence suggests that the success in using this tactic
relies on three particular elements namely,
 the magnitude and perceived severity of the negative
outcome;
 the probability of occurrence if no action is taken to
avoid it; and
 the likely availability and effectiveness of the
recommended course of action.Logical argument
Logical argument takes the form of reasoned appeal
based on the presentation of the available evidence. It is
not merely confined to the evidence itself but the con-
clusions emanating from it and the advantages of a par-
ticular course of action set against other alternatives.
The power of the argument is further enhanced by the
style of delivery, using slightly faster speech rate, an open
posture, few hesitations or expressed doubts and the use
of ‘intensifiers’ e.g. definitely, absolutely.
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The maxim, ‘You scratch my back and I’ll scratch yours’
is an apt way to sum up this approach that is essentially
an exchange of favours. It may entail giving something
in advance (pre-giving) in anticipation of the favour be-
ing repaid later or it may involve a conditional promise,
‘You do this for me now, and I’ll do that for you later’.
Moral appeals
This is an appeal to an individual’s sense of rightness
and responsibility where acceptance is likely to lead to
self-contentment, whereas rejection may induce feelings
of guilt e.g. positively responding to an appeal for a char-
itable cause.
Scale of request
This can take two forms: the ‘foot in the door’ or ‘door
in the face’ strategies. The first involves a small scale re-
quest, ‘Could we try this new treatment in one or two
patients’ but then escalating it to a higher demand e.g. a
controlled clinical trial. The second could begin with the
large demand but scaled down to make the request more
moderate and appealing.
Scarcity value
By rendering something as having limited or restricted
availability and presented with constraints of time, fi-
nance, volume or uniqueness, induces pressure to gain
early or immediate adoption. ‘if you can give approval
for the programme within the next 2 weeks we can have
the work completed within this current financial year’.
The relationship
This approach derives from the fact that we are more
likely to be influenced by people we like, are friendly with,
or for whom we have a high regard. Thus the building and
establishment of positive professional relationships will be
important to effective persuasion attempts. Moreover,Figure 2 Civil Society Organisations-Governance Constructive Engagehaving supporters from other disciplines will improve the
chances of success where there is seen to be an agreed
position to a particular course of action.Aversive stimulation
An extreme example of this tactic is the torture of an in-
dividual in order to extract information. At an everyday
level it is the persistent nagging of a parent by a child until
the parent accedes. In work it is the continued and deter-
mined lobbying of management in anticipation of gaining
a positive response that initially was not forthcoming.Structures
As indicated earlier, skills, structures and subject matter
are not exclusive elements and it could be argued that
structures, to some extent, form a part of the power di-
mension of influencing. On the one hand they reflect
more organisational influence in that they often repre-
sent a sizeable body of opinion, have credibility among
their peer organisations and are recognised by society at
large, particularly those that have a professional regula-
tory role allied to public protection. On the other hand
they may also reflect the systems or machinery of govern-
ment for the ordering of society and which can be used as
a vehicle through which influence can be exerted.
Although governments utilise the media to communi-
cate with their populations at large, they may also engage
with both national and local bodies that represent differ-
ent interest groups. In some countries, like the UK, there
are well established processes for public consultation that
facilitate comment and expression of individual interests.
Government consultation processes are therefore an op-
portunity for professional pharmaceutical bodies to make
their voice heard in areas where they have a legitimate
interest. Moreover, organisations like The Commonwealth
Foundation seek to promote participatory governance
among member countries (Figure 2) and indeed providement areas and Approaches [6].
Table 1 Examples of medicine related policies
Adverse medication events Prescription charges
Antimicrobial stewardship Purchasing of medicines
Availability of high cost specialist
medicines
Quality of Medicines
Essential medicine lists Reimbursement of dispensed
medication
Generic substitution Storage, safe handling and
administration
Medicines information for patients Use of patients own medicines
following hospital admission
Medicines legislative control Use of unlicensed (and off-label)
medicines
Partnership with the pharmaceutical
industry
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tives [6,7].
Outside a consultation process, representative bodies
have the potential to lobby local politicians or Government.
A number of national pharmaceutical bodies or associa-
tions have established a Public Affairs section to provide
for a conduit between their organisation and public repre-
sentatives. It is also important to appreciate the power of
the media to shape public opinion and government policy
and the influence that can be brought to bear through that
route. At the same time pharmaceutical organisations that
espouse standards of professional ethics allied to the deliv-
ery of pharmaceutical services need also to ensure that
those professional ethics are consistently applied to their
wider business.
Allied to engagement with policy makers, opportun-
ities can be created by, for example extending an invita-
tion to address a particular meeting or conference. This
will provide the opportunity to offer some briefing set-
ting out the roles of the organisation, the particular
contributions of the profession as well as highlighting
examples of innovative practice.
In the same way providing the opportunity for a public
representative, government official or Minister to visit a
particular practice site provides for further visibility of
the profession and a setting in which pharmaceutical mat-
ters can be discussed and explored. In addition, it can be a
good setting to elicit if a proposal or paper on a particular
matter would be welcomed.
Structures would also embrace established forums,
such as Review Groups, National Inquiries, Task Forces,
Specialist Committees, created to investigate particular
issues and make recommendations. In the health environ-
ment these are numerous, whether they concern the man-
agement of particular disease states, eg. management of
long term conditions, making provision for elderly care,
strategies to tackle communicable disease, inquiries into
adverse events. These provide opportunity for pharma-
ceutical representation, but also importantly to express
medicines management or pharmaceutical care perspec-
tives and options. In summary.
 Are there professional organisational structures that
allow for representation - national, regional, local?
 Are there media opportunities that enable
pharmacy’s voice to be heard?
 Are there Review or Task Groups that would enable
pharmaceutical involvement?
 Are there disease management or public health
collaborative ventures that pharmacists can
engage in?
 Where might the opportunity lie to invite a health
care policy maker or health minister to address a
meeting of pharmacists? Have you proposals at hand that could be readily
offered given the opportunity to put them forward –
‘You don’t get a second chance to make a first
impression!’
 Could you develop a proposal to support an
engagement process on a particular matter of local,
regional or national importance?
Subject
Getting an issue or topic onto the policy agenda may
prove particularly challenging and can require a good
understanding of, and ability to, navigate the public pol-
icy arena [8,9], Moreover, in any given area there can be
competing interests, for example, policies around rational
prescribing of medicines and the pressure from pharma-
ceutical companies to expand the sales of their products
[10]. However, the subject or the impact of the subject can
itself be influential in ensuring that it has a prominent
place in the healthcare policy agenda e.g. the risk of hos-
pital acquired infection, requiring a policy to be developed
or modified. Here it is the importance, urgency, exposure
to avoidable risk, cost, public concern that is likely to in-
fluence action being taken.
These factors apply to medicines more generally in
that they are the ubiquitous technology in health care,
consume a considerable proportion of health expend-
iture, contribute substantially to the management and
cure of disease but also are a recognised source of ad-
verse effects due to their pharmacological properties
and of adverse events due to errors in their use. They
therefore deserve a prominent place in health care pol-
icy making. Some examples of medicine related policies
are given in Table 1.
A worked example
How then might the significance of an issue for policy
development be demonstrated? Consider, for example,
adverse drug reactions (ADRs) that are often viewed as
Table 3 Financial implications for ‘A Country’ in
preventing adverse medication events in hospitals
Annual number of hospital admissions 500,000
No. of adverse medication events at a 1-2% level 5,000 - 10,000
At an average length of stay of 5 days 25,000 – 50,000
At an average cost of £300/day £7.5 m - £15 m
Potential savings (based on 50%-70% preventability) £3.75 m - £10.5 m
(NB Average length of stay and daily costs will be country specific).
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not be available but there is a considerable body of inter-
national research literature that indicates the level of risk
particularly in the context of hospital care. While there
is a range of values depending on the patient group, a
conservative estimate would be that 4 – 6% of all hospital
admissions are due to ADRs. The literature indicates that
some 50 -70% of these are preventable. Assuming know-
ledge of the number of hospital admissions it is possible
to work out the numbers likely to have been the result of
an ADR. Data on the average length of stay would give an
indication of the total bed days that could have been
avoided and at what cost. The worked example shows the
impact (Table 2).
Similarly, consideration of the published data on adverse
events (as distinct from adverse drug reactions) in hospi-
talized patients this occurs in almost 10% of patients, and
of these, some 10-20% are medication related [11]. Apply-
ing, therefore, a 1-2% incident level to the above scenario
would yield the following savings (Table 3).
However, the financial saving are not the only impact
of improved medication practice. Consideration should
also be given to the cost to the economy in terms of lost
working days, the opportunity costs to provide other
care, not to mention the human costs to the individual
patient, family or carers.
Having then defined the problem, it is possible to
begin to identify a potential range of options or solutions
to minimize its impact and how, in particular, pharma-
ceutical expertise can be applied. Such solutions may in-
clude prescribing support, formulary development, patient
adherence programmes, targeting of medications particu-
larly associated with risk e.g. insulin, digoxin, anticoagu-
lants, closer patient monitoring, reducing communication
failures through, for example, improved documentation or
information transfer.
This approach has proved successful, for example, in
Northern Ireland leading to the establishment of a
Government funded Pharmacist Governance team focused
on minimising the occurrence of medication-related ad-
verse events in hospital through a systems-based approach
to risk management [12]. Built upon the success of the
team and the contribution it has made to safer medicationTable 2 Financial implications for ‘A Country’ in
preventing hospitalisations due to adverse drug reactions
Annual number of hospital admissions 500,000
No. of admissions at a 4 -6% ADR incidence level 20,000 - 30,000
At an average length of stay of 5 days 100,000 – 150,000
At an average cost of £300/day £30 m - £45 m
Potential savings (based on 50%-70% preventability) £15 m - £31.5 m
(NB Average length of stay and daily costs will be country specific).practice, the team has been extended into primary care
[13,14]. Here the work has focused on:
 Encouraging the reporting of adverse incidents from
GPs and Community pharmacists
 Establishing an anonymous adverse incident
reporting system for community pharmacists
 Following up individual adverse incidents to ensure
learning and reduce the chance of a similar adverse
incident by the same practitioner
 Identifying and sharing learning from both named
and anonymous adverse incidents across
practitioners via regular newsletters and medicines
safety alerts
 Developing Standard Operating procedures (SOPs),
processes and audits for safer systems in general
practice, e.g. repeat prescribing, prescription
security, medication review
 Providing training to a range of audiences to
promote adverse incident reporting, learning and
implementation of safe systems
 Developing local learning resources and protocols
for national alerts to ensure their implementation in
primary care
 Developing systems and processes to oversee the safe
management of Controlled Drugs in primary care
What has resulted is a whole systems approach to medi-
cation safety. This includes processes for handling medica-
tion incidents identified at the interface, development of
medication incident categorisation to permit trend analysis
across both sectors and the identification and collaboration
on joint safety initiatives which support implementation of
national (UK wide) safety alerts.
This is but one example of influencing for change but
illustrative of the use and application of evidence to ad-
dress a critical issue, particularly using pharmaceutical
expertise. At a more macro level WHO has published a
framework for the development and implementation of
national drugs policies that can easily be adapted and
applied to more specific topics such as those in Table 1
[15]. In addition, allied to the implementation of medi-
cines policies, it is important to think about those who
will have a key input to effecting their application and
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or expanded. In that regard, pharmacists as regulated
professionals, are a central resource both from an infor-
mational point of view but also as an integral member of
the supply chain.Conclusion
This article has addressed three important components
in respect of influencing pharmaceutical policy namely,
the application of persuasive skills, the constructive use
of existing structures to engage with policy makers and
the identification of critical subject areas that, if addressed,
could enhance the delivery of health care and lead to bet-
ter health outcomes. Full engagement in these processes is
important for pharmacists in order to fulfill their full po-
tential as health care providers and more generally con-
tribute to the welfare of society.
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